Homology Medicines Inc (NASDAQ:FIXX) COO Siyamak Rasty sold 8,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $20.22, for a total value of $161,760.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Homology Medicines stock opened at $19.57 on Friday. The firm has a 50 day moving average price of $20.28. The firm has a market cap of $805.55 million, a PE ratio of -9.79 and a beta of 0.30. Homology Medicines Inc has a 12 month low of $15.07 and a 12 month high of $31.80.
Homology Medicines (NASDAQ:FIXX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.11). Homology Medicines had a negative net margin of 2,253.08% and a negative return on equity of 34.90%. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.00 million. On average, equities analysts expect that Homology Medicines Inc will post -2.32 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP raised its holdings in shares of Homology Medicines by 275.6% in the 4th quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock worth $36,525,000 after buying an additional 1,198,574 shares in the last quarter. BlackRock Inc. boosted its position in Homology Medicines by 134.3% in the 4th quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock valued at $32,656,000 after buying an additional 837,099 shares during the last quarter. VV Manager LLC bought a new position in Homology Medicines in the 4th quarter valued at $17,236,000. Vanguard Group Inc. boosted its position in Homology Medicines by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 473,945 shares of the company’s stock valued at $10,834,000 after buying an additional 3,504 shares during the last quarter. Finally, Vanguard Group Inc boosted its position in Homology Medicines by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 473,945 shares of the company’s stock valued at $10,834,000 after buying an additional 3,504 shares during the last quarter. 52.87% of the stock is owned by institutional investors and hedge funds.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.